ALTA-2530 / Sumitomo Pharma - LARVOL DELTA

ALTAVANT SCIENCES TO PRESENT DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530 (PRNewswire) - "Altavant Sciences...announced today that the company will make an oral presentation on preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans syndrome (BOS). Altavant will also share a poster presentation summarizing the research to understand patient insights in BOS/chronic lung allograft dysfunction (CLAD) at the International Society for Heart & Lung Transplantation (ISHLT) annual meeting, April 27-30, 2022, in Boston, MA."

Preclinical • Immunology • Respiratory Diseases

ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530 (GlobeNewswire) - "Altavant Sciences...announced today that the company made an oral presentation of preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans syndrome (BOS) at the International Society for Heart & Lung Transplantation (ISHLT) annual meeting in Boston, MA....Results of in vivo studies presented at ISHLT demonstrate that once-daily administration of aerosolized ALTA-2530 achieved distribution to the distal regions of the lung. In separate in vitro studies, ALTA-2530 demonstrated a significantly greater binding affinity for the IL-1 type 1 receptor than was achieved with IL-1α and IL-1β – the endogenous receptor ligands. ALTA-2530 also demonstrated potent inhibition of IL-1β stimulated expression of the proinflammatory cytokine IL-6."

Preclinical • Immunology • Respiratory Diseases